<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225965</url>
  </required_header>
  <id_info>
    <org_study_id>PPL-015</org_study_id>
    <nct_id>NCT01225965</nct_id>
  </id_info>
  <brief_title>Efficacy and Feasibility of Ectoin速 Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung</brief_title>
  <acronym>EFECT</acronym>
  <official_title>An Efficacy and Feasibility Study to Investigate the Effect of Ectoin速 Inhalation Solution (EIL) in Subjects With Inflammation and Airway Obstruction Followed by a Long Term Study Extension on the Prevention of Lung Function Decline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bitop AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bitop AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the physical inflammation inhibition effects of EIL (Ectoin-Hydro-Complex) in
      subjects of the established SALIA-cohort and the preventive effects on lung function decline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of inflammatory markers considered to be indicative for the protective efficacy of EIL in pulmonary inflammation in COPD</measure>
    <time_frame>Baseline and 28 days after treatment start</time_frame>
    <description>Change of biomarkers in spautum, exhaled breath condensate and serum after treatment compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Baseline and 28 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of lung function decline</measure>
    <time_frame>Baseline and 28 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline and 28 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue medication</measure>
    <time_frame>28 days (during treatment phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of adverse events</measure>
    <time_frame>28 days (during treatment phase)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function parameters</measure>
    <time_frame>28 days (during treatment phase)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>COPD</condition>
  <condition>Particulate Matter Induced Inflammation of the Lung</condition>
  <arm_group>
    <arm_group_label>EIL05, Inhalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 0,9% NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ectoin Inhalation Solution</intervention_name>
    <description>Once daily inhalation of Ectoin Inhalation Solution</description>
    <arm_group_label>EIL05, Inhalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily inhalation of Placebo Inhalation Solution</description>
    <arm_group_label>Placebo, 0,9% NaCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal females (75 - 80 years)

          -  FEV1/FVC &lt; 0,77 (in the investigation 2007/2008)

          -  Inflammatory markers TFN-alpha &gt; median or neutrophilic granulocytes &gt; median
             (investigation 2007/2008)

          -  Non smokers or ex smokers who have stopped smoking for longer than 6 months

        Exclusion Criteria:

          -  Participation in another clinical study in the previous month

          -  Severe concomitant disease which may have an impact on the study participation

          -  Hypersensitivity against Ectoin

          -  Myocardial infarction or apoplexy within the last year

          -  Uncontrolled hypertension: systolic blood pressure &gt;200 mmHg or diastolic pressure
             &gt;120 mmHg

          -  Known aortic aneurysm

          -  Other respiratory diseases (e.g. cystic fibrosis, alpha-1-Antitrypsin deficiency,
             sarcoidosis, allergic alveolitis, tuberculosis, etc.)

          -  Patients who have had treatment with live attenuated vaccinations within 14 days prior
             to screening visit (Inactivated influenza vaccination is acceptable, provided it is
             not administered within 7 days prior to screening visit)

          -  on investigators decision
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut f端r umweltmedizinische Forschung</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.iuf.uni-duesseldorf.de/englisch/home-e.htm</url>
    <description>Website of the Institut f端r umweltmedizinische Forschung</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>August 6, 2012</last_update_submitted>
  <last_update_submitted_qc>August 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Particulate Matter induced inflammation of the lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

